Johnson & Johnson stopped a mid‑stage trial of its anti‑tau monoclonal antibody posdinemab after an interim analysis found the drug did not outperform placebo on clinical endpoints, the company said. The decision follows a scheduled data review and will lead J&J to present full trial data at a later date. The failure dims prospects for tau‑targeting immunotherapies as a pathway to alter Alzheimer’s progression and may prompt competitors to reassess programs in the same mechanism. J&J’s move underscores the increasing rigor of interim futility assessments in neurodegeneration trials. Clarification: Anti‑tau antibodies aim to neutralize or clear tau protein aggregates, a hallmark of Alzheimer’s pathology thought to correlate with neurodegeneration.